Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...

Pharmacy benefit managers (PBMs) “invent all these special categories,” Cuban told Fortune’s Andrew Nusca. “They’re just ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...